NervGen Pharma Corp.
NGEN
$3.57
-$0.15-3.91%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -31.65M | -18.50M | -19.49M | -18.63M | -17.62M |
| Total Depreciation and Amortization | 39.90K | 41.20K | 41.80K | 42.70K | 61.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 17.18M | 5.33M | 6.11M | 5.11M | 4.66M |
| Change in Net Operating Assets | 466.00K | 1.14M | 989.20K | 719.40K | 601.40K |
| Cash from Operations | -13.97M | -11.99M | -12.35M | -12.76M | -12.30M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 72.20K | 72.10K | 72.30K | 60.20K | 42.60K |
| Cash from Investing | 72.20K | 72.10K | 72.30K | 60.20K | 42.60K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -100.80K | -100.80K | -100.80K | -100.80K | -100.80K |
| Issuance of Common Stock | 24.76M | 8.12M | 7.31M | 2.55M | 24.43M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -892.80K | -685.40K | -604.80K | -487.60K | -1.63M |
| Cash from Financing | 17.05M | 5.27M | 4.74M | 1.39M | 16.82M |
| Foreign Exchange rate Adjustments | 312.90K | -225.30K | -284.50K | -118.30K | -217.50K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.47M | -6.88M | -7.82M | -11.43M | 4.35M |